{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-056748","form_type":"8-K","ticker":null,"cik":"0000786947","company_name":"ACURA PHARMACEUTICALS, INC","filed_at":"2026-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.725289+00:00","generated_at":"2026-05-14T22:19:21.532855+00:00","sec_items":["1.01","2.01","2.03","9.01"],"event_type":"debt","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Acura's debt to related party grows to $10.3M; warns of possible shutdown without new financing by May-end","bullets":["Received four $100,000 loans from Abuse Deterrent Pharma on March 30, April 3, April 20, May 5, 2026, bringing principal to $10,294,279.","Accrued interest ~$1,090,000 as of May 5; interest rate 5.25% (7.5% on default).","Without additional financing by end of May 2026, company will need to scale back operations, furlough employees, or seek bankruptcy.","AD Pharma, which owns ~65% of Acura's common stock, is controlled by Mr. Schutte, who also owns ~13% directly."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-056748","json":"https://secwatch.observer/filing/0001104659-26-056748.json","markdown":"https://secwatch.observer/filing/0001104659-26-056748.md","text":"https://secwatch.observer/filing/0001104659-26-056748.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/786947/000110465926056748/0001104659-26-056748-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/786947/000110465926056748/tm2613771d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T22:19:21.532855+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5bbe4eca4279586b3c2d8f4d905216cae3ccb86f","claim":"ACURA PHARMACEUTICALS, INC incurred loan of $100,000 with Abuse Deterrent Pharma, LLC at 5.25%.","evidence_excerpt":"On each of March 30, 2026, April 3, 2026, April 20, 2026 and May 5, 2026, we received loans of $100,000 from Abuse Deterrent Pharma, LLC (“AD Pharma”).","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/786947/000110465926056748/0001104659-26-056748-index.htm","confidence":0.9}],"comparable_filings":[{"accession":"0001213900-26-053894","ticker":"TBH","company_name":"Brag House Holdings, Inc.","filed_at":"2026-05-08T23:59:59+00:00","headline":"Brag House issues $2.5M convertible notes at 25% OID; proceeds for House of Doge merger","event_type":"debt","sec_items":["1.01","2.03","3.02","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: debt_financing","same SEC item: 1.01, 2.03, 9.01","same event type: debt","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-053894","json":"https://secwatch.observer/filing/0001213900-26-053894.json","markdown":"https://secwatch.observer/filing/0001213900-26-053894.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1903595/000121390026053894/0001213900-26-053894-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1903595/000121390026053894/ea0289773-8k_braghouse.htm"},"side_by_side_evidence":{"fact_type":"debt_financing","source_excerpt":"On each of March 30, 2026, April 3, 2026, April 20, 2026 and May 5, 2026, we received loans of $100,000 from Abuse Deterrent Pharma, LLC (“AD Pharma”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/786947/000110465926056748/0001104659-26-056748-index.htm","comparable_excerpt":"The issuance of the Notes in the aggregate original principal amount of $2,500,000 constitutes the creation of a direct financial obligation of the Company. The Notes bear interest at 12.0% per annum, mature on February 4, 2027","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1903595/000121390026053894/0001213900-26-053894-index.htm"}},{"accession":"0001492691-26-000042","ticker":"KNX","company_name":"Knight-Swift Transportation Holdings Inc.","filed_at":"2026-05-08T23:59:59+00:00","headline":"Knight-Swift closes $1.5B convertible note offering at 1.00% due 2031; proceeds used to repay term loans and revolver","event_type":"debt","sec_items":["1.01","2.03","3.02","8.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: debt_financing","same SEC item: 1.01, 2.03, 9.01","same event type: debt","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001492691-26-000042","json":"https://secwatch.observer/filing/0001492691-26-000042.json","markdown":"https://secwatch.observer/filing/0001492691-26-000042.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1492691/000149269126000042/0001492691-26-000042-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1492691/000149269126000042/knx-20260505.htm"},"side_by_side_evidence":{"fact_type":"debt_financing","source_excerpt":"On each of March 30, 2026, April 3, 2026, April 20, 2026 and May 5, 2026, we received loans of $100,000 from Abuse Deterrent Pharma, LLC (“AD Pharma”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/786947/000110465926056748/0001104659-26-056748-index.htm","comparable_excerpt":"On May 8, 2026, Knight-Swift Transportation Holdings Inc. (the \"Company\") completed its previously announced private offering (the \"Offering\") of $1.5 billion aggregate principal amount of 1.00% Convertible Senior Notes due 2031","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1492691/000149269126000042/0001492691-26-000042-index.htm"}},{"accession":"0001104659-26-057128","ticker":"PUMP","company_name":"ProPetro Holding Corp.","filed_at":"2026-05-07T23:59:59+00:00","headline":"ProPetro issues $690M zero-coupon convertible notes due 2031, expands credit facility","event_type":"debt","sec_items":["1.01","2.03","3.02","8.01","9.01"],"materiality_score":0.8,"calibrated_materiality_score":0.8,"match_reasons":["same fact type: debt_financing","same SEC item: 1.01, 2.03, 9.01","same event type: debt","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-057128","json":"https://secwatch.observer/filing/0001104659-26-057128.json","markdown":"https://secwatch.observer/filing/0001104659-26-057128.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1680247/000110465926057128/0001104659-26-057128-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1680247/000110465926057128/tm2613899d1_8k.htm"},"side_by_side_evidence":{"fact_type":"debt_financing","source_excerpt":"On each of March 30, 2026, April 3, 2026, April 20, 2026 and May 5, 2026, we received loans of $100,000 from Abuse Deterrent Pharma, LLC (“AD Pharma”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/786947/000110465926056748/0001104659-26-056748-index.htm","comparable_excerpt":"On May 7, 2026, ProPetro Holding Corp. (the “ Company ”), issued $690 million aggregate principal amount of its 0.00% Convertible Senior Notes due 2031","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1680247/000110465926057128/0001104659-26-057128-index.htm"}},{"accession":"0001104659-26-057138","ticker":"OCGN","company_name":"Ocugen, Inc.","filed_at":"2026-05-07T23:59:59+00:00","headline":"Ocugen completes $115M convertible note offering at 6.75%, repays Avenue loan","event_type":"debt","sec_items":["1.01","1.02","2.02","2.03","3.02","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: debt_financing","same SEC item: 1.01, 2.03, 9.01","same event type: debt","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-057138","json":"https://secwatch.observer/filing/0001104659-26-057138.json","markdown":"https://secwatch.observer/filing/0001104659-26-057138.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1372299/000110465926057138/0001104659-26-057138-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1372299/000110465926057138/tm2613898d1_8k.htm"},"side_by_side_evidence":{"fact_type":"debt_financing","source_excerpt":"On each of March 30, 2026, April 3, 2026, April 20, 2026 and May 5, 2026, we received loans of $100,000 from Abuse Deterrent Pharma, LLC (“AD Pharma”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/786947/000110465926056748/0001104659-26-056748-index.htm","comparable_excerpt":"On May 7, 2026, Ocugen, Inc. (the “Company”) completed its previously announced private offering (the “offering”) of $115.0 million aggregate principal amount of 6.75% Convertible Senior Notes due 2034 (the “notes”).","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1372299/000110465926057138/0001104659-26-057138-index.htm"}},{"accession":"0001193125-26-208905","ticker":"CORZ","company_name":"Core Scientific, Inc./tx","filed_at":"2026-05-06T23:59:59+00:00","headline":"Core Scientific subsidiary prices $3.3B of 7.750% senior secured notes due 2031","event_type":"debt","sec_items":["1.01","1.02","2.03","8.01","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same fact type: debt_financing","same SEC item: 1.01, 2.03, 9.01","same event type: debt","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-208905","json":"https://secwatch.observer/filing/0001193125-26-208905.json","markdown":"https://secwatch.observer/filing/0001193125-26-208905.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1839341/000119312526208905/0001193125-26-208905-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1839341/000119312526208905/d47435d8k.htm"},"side_by_side_evidence":{"fact_type":"debt_financing","source_excerpt":"On each of March 30, 2026, April 3, 2026, April 20, 2026 and May 5, 2026, we received loans of $100,000 from Abuse Deterrent Pharma, LLC (“AD Pharma”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/786947/000110465926056748/0001104659-26-056748-index.htm","comparable_excerpt":"On May 6, 2026, Core Scientific Finance I LLC (the “Issuer”), a wholly-owned indirect subsidiary of Core Scientific, Inc. (“Core Scientific”), completed its previously announced private offering (the “Offering”) of $3.3 billion aggregate principal amount of its 7.750% Senior Secured Notes due 2031 (the “Notes”).","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1839341/000119312526208905/0001193125-26-208905-index.htm"}},{"accession":"0001193125-26-206397","ticker":"BNZI","company_name":"Banzai International, Inc.","filed_at":"2026-05-05T23:59:59+00:00","headline":"Banzai exchanges shares for debt; issued 1.47M shares, note reduced to $819K","event_type":"debt","sec_items":["1.01","2.03","3.02","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: debt_financing","same SEC item: 1.01, 2.03, 9.01","same event type: debt","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-206397","json":"https://secwatch.observer/filing/0001193125-26-206397.json","markdown":"https://secwatch.observer/filing/0001193125-26-206397.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1826011/000119312526206397/0001193125-26-206397-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1826011/000119312526206397/bnzi-20251217.htm"},"side_by_side_evidence":{"fact_type":"debt_financing","source_excerpt":"On each of March 30, 2026, April 3, 2026, April 20, 2026 and May 5, 2026, we received loans of $100,000 from Abuse Deterrent Pharma, LLC (“AD Pharma”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/786947/000110465926056748/0001104659-26-056748-index.htm","comparable_excerpt":"in the principal amount due under the Note (the “Forbearance Fee”). After giving effect to the Forbearance Fee and the Exchange, the outstanding balance under the Note was $1,839,432.50. The Company also agreed to pay all of Agile’s reasonable costs and expenses, in an amount not to exceed $10,000. Following the initial Exchange, the Company, Agile and the","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1826011/000119312526206397/0001193125-26-206397-index.htm"}},{"accession":"0001213900-26-051931","ticker":"RENX","company_name":"RenX Enterprises Corp.","filed_at":"2026-05-05T23:59:59+00:00","headline":"RenX Enterprises raises up to $100M via tranched convertible note and warrant private placement","event_type":"debt","sec_items":["1.01","2.03","3.02","7.01","8.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: debt_financing","same SEC item: 1.01, 2.03, 9.01","same event type: debt","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-051931","json":"https://secwatch.observer/filing/0001213900-26-051931.json","markdown":"https://secwatch.observer/filing/0001213900-26-051931.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1959023/000121390026051931/0001213900-26-051931-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1959023/000121390026051931/ea0288854-8k_renx.htm"},"side_by_side_evidence":{"fact_type":"debt_financing","source_excerpt":"On each of March 30, 2026, April 3, 2026, April 20, 2026 and May 5, 2026, we received loans of $100,000 from Abuse Deterrent Pharma, LLC (“AD Pharma”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/786947/000110465926056748/0001104659-26-056748-index.htm","comparable_excerpt":"Purchase Agreement,\nthe Company (i) issued and sold to the Purchasers, at the initial closing on May 4, 2026 (the “Initial Closing”), Notes in\nthe aggregate principal amount of $6,300,000 (the “Initial Notes”) and warrants (the “Initial Warrants”) to purchase\nan aggregate of 3,917,099 shares of Common Stock (which is equal to 180% of the face value of the Initial","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1959023/000121390026051931/0001213900-26-051931-index.htm"}},{"accession":"0001193125-26-204193","ticker":"TBCH","company_name":"Turtle Beach Corp","filed_at":"2026-05-04T23:59:59+00:00","headline":"Turtle Beach closes $85M term loan and $80M ABL; $56M buyback capacity remains","event_type":"debt","sec_items":["1.01","2.03","7.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: debt_financing","same SEC item: 1.01, 2.03, 9.01","same event type: debt","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-204193","json":"https://secwatch.observer/filing/0001193125-26-204193.json","markdown":"https://secwatch.observer/filing/0001193125-26-204193.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1493761/000119312526204193/0001193125-26-204193-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1493761/000119312526204193/d125698d8k.htm"},"side_by_side_evidence":{"fact_type":"debt_financing","source_excerpt":"On each of March 30, 2026, April 3, 2026, April 20, 2026 and May 5, 2026, we received loans of $100,000 from Abuse Deterrent Pharma, LLC (“AD Pharma”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/786947/000110465926056748/0001104659-26-056748-index.htm","comparable_excerpt":"a US commitment in an amount equal to $50,000,000 or $65,000,000 based on the season","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1493761/000119312526204193/0001193125-26-204193-index.htm"}}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}